BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 29475458)

  • 1. Clinical significance of polyglutamylation in primary central nervous system lymphoma.
    Shinojima N; Fujimoto K; Makino K; Todaka K; Yamada K; Mikami Y; Oda K; Nakamura K; Jono H; Kuratsu JI; Nakamura H; Yano S; Mukasa A
    Acta Neuropathol Commun; 2018 Feb; 6(1):15. PubMed ID: 29475458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma.
    Fujimoto K; Shinojima N; Hayashi M; Nakano T; Ichimura K; Mukasa A
    Neurooncol Adv; 2020; 2(1):vdaa084. PubMed ID: 32793886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients.
    Kasenda B; Rehberg M; Thürmann P; Franzem M; Veelken H; Fritsch K; Schorb E; Finke J; Lebiedz D; Illerhaus G
    Ann Hematol; 2012 Aug; 91(8):1257-64. PubMed ID: 22456893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.
    Joerger M; Huitema AD; Krähenbühl S; Schellens JH; Cerny T; Reni M; Zucca E; Cavalli F; Ferreri AJ
    Br J Cancer; 2010 Feb; 102(4):673-7. PubMed ID: 20125159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma.
    Blasco H; Senecal D; Le Gouge A; Pinard E; Benz-de Bretagne I; Colombat P; Hulot JS; Chatelut E; Le Guellec C
    Br J Clin Pharmacol; 2010 Sep; 70(3):367-75. PubMed ID: 20716237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
    Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
    Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboxypeptidase G2 rescue after high-dose methotrexate.
    DeAngelis LM; Tong WP; Lin S; Fleisher M; Bertino JR
    J Clin Oncol; 1996 Jul; 14(7):2145-9. PubMed ID: 8683248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells.
    Hayano A; Takashima Y; Yamanaka R
    Int J Clin Oncol; 2019 Sep; 24(9):1020-1029. PubMed ID: 30993483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.
    Kasenda B; Ferreri AJ; Marturano E; Forst D; Bromberg J; Ghesquieres H; Ferlay C; Blay JY; Hoang-Xuan K; Pulczynski EJ; Fosså A; Okoshi Y; Chiba S; Fritsch K; Omuro A; O'Neill BP; Bairey O; Schandelmaier S; Gloy V; Bhatnagar N; Haug S; Rahner S; Batchelor TT; Illerhaus G; Briel M
    Ann Oncol; 2015 Jul; 26(7):1305-13. PubMed ID: 25701456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
    Khan RB; Shi W; Thaler HT; DeAngelis LM; Abrey LE
    J Neurooncol; 2002 Jun; 58(2):175-8. PubMed ID: 12164690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.
    Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T; Fukushima T
    J Neurooncol; 2003 May; 63(1):87-95. PubMed ID: 12814260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma.
    Isono T; Hira D; Morikochi A; Fukami T; Ueshima S; Nozaki K; Terada T; Morita SY
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00883. PubMed ID: 34664791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose methotrexate for elderly patients with primary CNS lymphoma.
    Zhu JJ; Gerstner ER; Engler DA; Mrugala MM; Nugent W; Nierenberg K; Hochberg FH; Betensky RA; Batchelor TT
    Neuro Oncol; 2009 Apr; 11(2):211-5. PubMed ID: 18757775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma.
    Jahnke K; Korfel A; Martus P; Weller M; Herrlinger U; Schmittel A; Fischer L; Thiel E;
    Ann Oncol; 2005 Mar; 16(3):445-9. PubMed ID: 15653703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolome Analysis Reveals Excessive Glycolysis via PI3K/AKT/mTOR and RAS/MAPK Signaling in Methotrexate-Resistant Primary CNS Lymphoma-Derived Cells.
    Takashima Y; Hayano A; Yamanaka R
    Clin Cancer Res; 2020 Jun; 26(11):2754-2766. PubMed ID: 32108030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
    Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
    Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.
    Estephan F; Ye X; Dzaye O; Wagner-Johnston N; Swinnen L; Gladstone DE; Ambinder R; Kamson DO; Lambrecht S; Grossman SA; Lin DDM; Holdhoff M
    J Neurooncol; 2019 Dec; 145(3):461-466. PubMed ID: 31621040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese.
    Han X; Ji Y; Ouyang M; Zhu T; Zhou D
    Sci Rep; 2017 Dec; 7(1):17053. PubMed ID: 29213063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.